TD Cowen lowered the firm’s price target on Ascendis Pharma (ASND) to $153 from $160 and keeps a Buy rating on the shares. The firm said its target moved lower folowing the Q3 Skytrofa revenue miss and lowered guidance.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND: